At the start of 2024, AstraZeneca finalized the purchase of two biotechnological companies conducting advanced clinical research in the field of oncology, autoimmune diseases, and countering serious viral diseases of the respiratory system.
“The acquisition of both companies stems from AstraZeneca’s strategic goals, which include developing innovative therapies for cancers and autoimmune diseases, and supporting prevention and meeting growing needs in the prevention of infectious diseases of the respiratory system. Our company continues to expand its commitment to patients by using the achievements of science to overcome previously unsolved health problems. At AstraZeneca, we value cooperation because, through it, we can create a better future and a healthy society,” said Edyta Wojtkiewicz, CFO of AstraZeneca.
Gracell Biotechnologies Inc., purchased in February, is a global biotechnology company conducting clinical research in the area of innovative cell therapies for the treatment of cancer and autoimmune diseases. This acquisition expands AstraZeneca’s offer to include GC012F, a chimeric antigen receptor (CAR) T cell therapy with a B lymphocyte maturation antigen (BCMA) dual targeted to CD19, developed on the new FasT CAR-T platform. This therapy has great potential in the treatment of blood cancers and autoimmune diseases. Gracell will function as a wholly-owned subsidiary of AstraZeneca.
Icosavax, a biotechnology company acquired by AstraZeneca in January, focuses on developing vaccines using an innovative virus-like particle (VLP) protein platform. The merger with Icosavax enables the expansion of AstraZeneca’s portfolio in preventing RSV and human metapneumovirus (hMPV). These viruses are a major cause of severe respiratory infections and hospitalization of adults aged 60+ and individuals with chronic diseases, such as cardiovascular, kidney, and respiratory diseases. As a result of the acquisition, Icosavax has become a subsidiary of AstraZeneca.
